导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 26.77% | 200/4773 |
| 近一周 | 2.14% | 186/5465 |
| 近一月 | -2.73% | 1853/5421 |
| 近一季 | -4.54% | 1839/5231 |
| 近半年 | 17.95% | 283/4920 |
| 近一年 | 32.05% | 211/4394 |
| 近两年 | 171.63% | 152/2954 |
| 近三年 | 110.56% | 122/2253 |
| 成立以来 | 72.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.89% 2955/4961 |
69.64% 292/5312 |
- - |
- - |
| 2025 | 49.82% 475/4813 |
8.93% 425/3635 |
1.36% 2366/4076 |
38.23% 853/4524 |
-1.84% 3023/4813 |
| 2024 | 12.04% 1279/3463 |
-10.06% 2315/2808 |
-2.66% 1222/3014 |
16.41% 1466/3129 |
9.94% 296/3463 |
| 2023 | 2.80% 303/2656 |
25.66% 95/2280 |
-7.43% 1852/2385 |
-10.76% 2020/2515 |
-0.98% 276/2655 |
| 2022 | -29.17% 1592/2207 |
-21.85% 1660/1919 |
-0.25% 1608/2016 |
-13.07% 827/2113 |
4.53% 539/2208 |
| 2021 | 14.98% 314/1822 |
-8.73% 1094/1255 |
18.18% 175/1330 |
-3.68% 654/1466 |
10.68% 97/1822 |
| 2020 | 7.75% 863/1250 |
-0.06% 177/1028 |
19.44% 298/1067 |
-2.68% 1079/1164 |
-7.25% 1153/1184 |
| 2019 | 69.07% 29/1092 |
46.47% 19/754 |
-9.43% 652/804 |
16.67% 13/850 |
9.24% 243/918 |
| 2018 | -31.25% 491/834 |
- - |
- - |
- - |
-14.59% 588/691 |
| 2017 | 0.58% 474/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 南方中证500信息技术联接A VS. 长安沪深300非周期A(740101) |